2型糖尿病的发生率在全球范围内呈逐年增高趋势，已成为威胁人们健康和生命的非传染性疾病。埃格列净（Ertugliflozin，Steglatro^®）是钠-葡萄糖共转运蛋白2抑制剂，由美国辉瑞公司和德国默克公司合作研发，于2018年3月被美国FDA批准用于改善2型糖尿病成年患者的血糖控制，可单药治疗或与其他降血糖药物联合使用。对埃格列净的基本信息、药理学、用药注意事项和临床试验等进行介绍。

The incidence rate of type 2 diabetes mellitus (T2DM) increased year by year in the worldwide has become a non communicable disease that threatens human health and life. Ertugliflozin (Steglatro^TM) is an orally sodium glucose co-transporter 2 inhibitor developed by Merck and Pfizer Pharmaceuticals Ltd as a treatment for T2DM. In March 2018, the novel drug has recently been approved by the US FDA as an adjunct to diet and exercises to improve glycaemic control in adults with T2DM as either monotherapy or in combination with other hypoglycemic agents. The base information, pharmacology, clinical evaluation and safety of empagliflozin were reviewed in this article.